Christopher S. Henney, Director at Cascadian Therapeutics, Inc. (CASC), bought 50,648 shares at $4.11 ($208K) on 2017-01-30, disclosed to the SEC on 2017-02-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.11 | 25,324 | $104K | 50.0% |
| 2 | $4.11 | 25,324 | $104K | 50.0% |
| Total | $4.11 avg | 50,648 | $208K | 100% |
| Filing → |
| PRTA | SELL | 2021-06-29 | $1.1M | — | Filing → |
| PRTA | SELL | 2017-09-29 | $63K | — | Filing → |
| PRTA | SELL | 2017-07-19 | $331K | — | Filing → |